Eqis Capital Management, Inc. Biocryst Pharmaceuticals Inc Transaction History
Eqis Capital Management, Inc.
- $1.19 Billion
- Q2 2025
A detailed history of Eqis Capital Management, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 24,581 shares of BCRX stock, worth $172,558. This represents 0.02% of its overall portfolio holdings.
Number of Shares
24,581Holding current value
$172,558% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding BCRX
# of Institutions
316Shares Held
201MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$144 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$140 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$59.7 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$59.4 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$40.1 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.31B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...